An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose RP2D in Adults with Advanced Hepatocellular Carcinoma HCC who are not Candidates for Standard-Of-Care Therapy.

Brief Summary

Type:
Liver

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT04502082

Study #:
STUDY00145792

Start Date:
Oct 11, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04502082

View Complete Trial Details & Eligibility at ClinicalTrials.gov